Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02732015 · ClinicalTrials.gov registry record · Phase 2
Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02732015: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02732015 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02732015, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well rolapitant hydrochloride works in preventing nausea/vomiting in patients with sarcoma receiving chemotherapy. Antiemetic drugs, such as rolapitant hydrochloride, may help control or prevent nausea and vomiting in patients treated with chemotherapy.
Interventions
- DRUG Doxorubicin
- OTHER Laboratory Biomarker Analysis
- DRUG Dexamethasone
- DRUG Ifosfamide
- DRUG Fosaprepitant Dimeglumine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2016-10-12 |
| Est. Completion | 2020-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02732015
The ClinicalTrials.gov registry entry for NCT02732015 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT02732015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02732015 about?
NCT02732015 is a clinical study titled "Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy". This randomized phase II trial studies how well rolapitant hydrochloride works in preventing nausea/vomiting in patients with sarcoma receiving chemotherapy. Antiemetic drugs, such as rolapitant hydrochloride, may help control or prevent nausea and vomiting in patients treated with chemotherapy.
What is the current status of trial NCT02732015?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2016-10-12. Estimated completion is 2020-07-10.
What interventions are being tested in trial NCT02732015?
The interventions under investigation include: Doxorubicin (DRUG), Laboratory Biomarker Analysis (OTHER), Dexamethasone (DRUG), Ifosfamide (DRUG), Fosaprepitant Dimeglumine (DRUG).
Who is sponsoring clinical trial NCT02732015?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.